Skip to main content
Erschienen in: Journal of Hematopathology 1/2018

06.02.2018 | Case Report

Primary lymphomatous presentation of hairy cell leukemia as osteolytic vertebral lesions: a case report

verfasst von: Jinming Song, Hailing Zhang, Xiaohui Zhang, Lynn Moscinski, Haipeng Shao

Erschienen in: Journal of Hematopathology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Hairy cell leukemia (HCL) is a rare and indolent mature B cell neoplasm. Most patients with HCL have excellent response to purine analogs and BRAF inhibitors. Therefore, it is clinically important to identify and differentiate HCL from other B cell neoplasms. HCL is predominantly found in the peripheral blood, bone marrow, or spleen. HCL presenting initially or solely in unusual sites is extremely rare (approximately ten or fewer). We hereby report a unique case of HCL presenting as vertebral osteolytic and epidural mass lesions without bone marrow, spleen, or peripheral blood involvement. The patient was a 53-year-old male with acute and chronic radicular pain down the posterior aspect of bilateral thighs. Imaging study with MRI demonstrated a L4 posterior vertebral osteolytic mass lesion, extending into the spinal canal, and a second right sacral S1 lesion extending into the sacral iliac joint. These two noncontiguous lesions were thought to be consistent with metastatic cancer or sarcoma, and the specimen was submitted to non-hematopoietic pathologist for diagnosis without flow cytometry. Initial immunohistochemical stains were ordered for solid tumor markers, which were all negative. As part of the workup, immunostain for BRAF V600E (VE1) was ordered for melanoma, and CD138 and cyclin D1 for myeloma, which returned positive and suggested the possibility of hairy cell leukemia. Additional workup for hairy cell leukemia confirmed the diagnosis. HCL typically presents with peripheral blood, bone marrow, or spleen involvement, while mass lesions in other sites are rare. High index of suspicion is essential for the correct diagnosis of HCL in mass lesions at unusual sites. In the absence of initial hematopathological workup and flow cytometry, HCL presenting as solid mass in unusual locations is misdiagnosed most likely as marginal zone B cell lymphoma (mucosa-associated lymphoid tissue (MALT) lymphoma). The expression of cyclin D1, TRAP, annexin A1, and BRAF V600E mutation would confirm the diagnosis of HCL. The main differentials include MALT lymphoma, mantle cell lymphoma (MCL), and hairy cell leukemia variant (HCLv). This case report will be interesting for the clinicians and pathologists alike and broaden the spectrum of clinical presentation of lymphomatous HCL.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, World Health Organization Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, World Health Organization
3.
Zurück zum Zitat Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K (1992) A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80(9):2203–2209PubMed Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K (1992) A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80(9):2203–2209PubMed
5.
Zurück zum Zitat Robak T, Blasinska-Morawiec M, Blonski J et al (1999) 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 62(1):49–56CrossRefPubMed Robak T, Blasinska-Morawiec M, Blonski J et al (1999) 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 62(1):49–56CrossRefPubMed
6.
Zurück zum Zitat Tallman MS, Hakimian D, Rademaker AW, Zanzig C, Wollins E, Rose E, Peterson LC (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88(6):1954–1959PubMed Tallman MS, Hakimian D, Rademaker AW, Zanzig C, Wollins E, Rose E, Peterson LC (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88(6):1954–1959PubMed
15.
17.
Zurück zum Zitat Akarca AU, Shende VH, Ramsay AD, Diss T, Pane-Foix M, Rizvi H, Calaminici MR, Grogan TM, Linch D, Marafioti T (2013) BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol 162(6):848–851. https://doi.org/10.1111/bjh.12429 CrossRefPubMed Akarca AU, Shende VH, Ramsay AD, Diss T, Pane-Foix M, Rizvi H, Calaminici MR, Grogan TM, Linch D, Marafioti T (2013) BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol 162(6):848–851. https://​doi.​org/​10.​1111/​bjh.​12429 CrossRefPubMed
18.
Zurück zum Zitat Wang XJ, Kim A, Li S (2014) Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. Int J Clin Exp Pathol 7(7):4323–4328PubMedPubMedCentral Wang XJ, Kim A, Li S (2014) Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. Int J Clin Exp Pathol 7(7):4323–4328PubMedPubMedCentral
23.
25.
Zurück zum Zitat Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E (2015) BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood 125(8):1207–1216. https://doi.org/10.1182/blood-2014-10-603100 CrossRefPubMedPubMedCentral Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E (2015) BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood 125(8):1207–1216. https://​doi.​org/​10.​1182/​blood-2014-10-603100 CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, Baldini L, Capnist G, Chisesi T, di Celle PF, Invernizzi R, Lauria F, Truini M, Resegotti L, Silingardi V, Damasio EE (1994) Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 5(8):725–731. https://doi.org/10.1093/oxfordjournals.annonc.a058977 CrossRefPubMed Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, Baldini L, Capnist G, Chisesi T, di Celle PF, Invernizzi R, Lauria F, Truini M, Resegotti L, Silingardi V, Damasio EE (1994) Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 5(8):725–731. https://​doi.​org/​10.​1093/​oxfordjournals.​annonc.​a058977 CrossRefPubMed
34.
Zurück zum Zitat Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733–1747. https://doi.org/10.1056/NEJMoa1506583 CrossRefPubMedPubMedCentral Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733–1747. https://​doi.​org/​10.​1056/​NEJMoa1506583 CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500–504. https://doi.org/10.1038/nature11183 CrossRefPubMedPubMedCentral Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500–504. https://​doi.​org/​10.​1038/​nature11183 CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387–390. https://doi.org/10.1038/nature10662 CrossRefPubMedPubMedCentral Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387–390. https://​doi.​org/​10.​1038/​nature10662 CrossRefPubMedPubMedCentral
Metadaten
Titel
Primary lymphomatous presentation of hairy cell leukemia as osteolytic vertebral lesions: a case report
verfasst von
Jinming Song
Hailing Zhang
Xiaohui Zhang
Lynn Moscinski
Haipeng Shao
Publikationsdatum
06.02.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Hematopathology / Ausgabe 1/2018
Print ISSN: 1868-9256
Elektronische ISSN: 1865-5785
DOI
https://doi.org/10.1007/s12308-017-0315-x

Weitere Artikel der Ausgabe 1/2018

Journal of Hematopathology 1/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie